101 related articles for article (PubMed ID: 7910296)
1. Suppression of HIV production in resting lymphocytes by combining didanosine and hydroxamate compounds.
Malley SD; Grange JM; Hamedi-Sangsari F; Vila JR
Lancet; 1994 May; 343(8908):1292. PubMed ID: 7910296
[No Abstract] [Full Text] [Related]
2. In vitro comparison of selected triple-drug combinations for suppression of HIV-1 replication: the Inter-Company Collaboration Protocol.
St Clair MH; Pennington KN; Rooney J; Barry DW
J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 2():S83-91. PubMed ID: 7552518
[TBL] [Abstract][Full Text] [Related]
3. [Is resistance of human immunodeficiency viruses (HIV) to nucleoside analogs an indication for their combined use?].
Pépin JM; Simon F; Brun-Vezinet F
Pathol Biol (Paris); 1993 Oct; 41(8 Pt 2):788-93. PubMed ID: 8309722
[TBL] [Abstract][Full Text] [Related]
4. Synergistic inhibition of HIV-1 in activated and resting peripheral blood mononuclear cells, monocyte-derived macrophages, and selected drug-resistant isolates with nucleoside analogues combined with a natural product, resveratrol.
Heredia A; Davis C; Redfield R
J Acquir Immune Defic Syndr; 2000 Nov; 25(3):246-55. PubMed ID: 11115955
[TBL] [Abstract][Full Text] [Related]
5. Effects of the Th1 and Th2 stimulatory cytokines interleukin-12 and interleukin-4 on human immunodeficiency virus replication.
Foli A; Saville MW; Baseler MW; Yarchoan R
Blood; 1995 Apr; 85(8):2114-23. PubMed ID: 7718882
[TBL] [Abstract][Full Text] [Related]
6. Disparate actions of hydroxyurea in potentiation of purine and pyrimidine 2',3'-dideoxynucleoside activities against replication of human immunodeficiency virus.
Gao WY; Johns DG; Chokekuchai S; Mitsuya H
Proc Natl Acad Sci U S A; 1995 Aug; 92(18):8333-7. PubMed ID: 7667290
[TBL] [Abstract][Full Text] [Related]
7. Highly specific inhibition of human immunodeficiency virus type 1 by a novel 6-substituted acyclouridine derivative.
Baba M; Tanaka H; De Clercq E; Pauwels R; Balzarini J; Schols D; Nakashima H; Perno CF; Walker RT; Miyasaka T
Biochem Biophys Res Commun; 1989 Dec; 165(3):1375-81. PubMed ID: 2575380
[TBL] [Abstract][Full Text] [Related]
8. Synergistic inhibition of replication of human immunodeficiency virus type 1, including that of a zidovudine-resistant isolate, by zidovudine and 2',3'-dideoxycytidine in vitro.
Eron JJ; Johnson VA; Merrill DP; Chou TC; Hirsch MS
Antimicrob Agents Chemother; 1992 Jul; 36(7):1559-62. PubMed ID: 1324648
[TBL] [Abstract][Full Text] [Related]
9. In-vitro activity of zidovudine, zalcitabine, and didanosine against mycoplasmas.
Ostashewski PM; Houston SC; Robertson JA
Lancet; 1993 Nov; 342(8881):1242-3. PubMed ID: 7901563
[No Abstract] [Full Text] [Related]
10. Synergistic inhibition of human immunodeficiency virus isolates (including 3'-azido-3'-deoxythymidine-resistant isolates) by foscarnet in combination with 2',3'-dideoxyinosine or 2',3'-dideoxycytidine.
Palmer S; Harmenberg J; Cox S
Antimicrob Agents Chemother; 1996 May; 40(5):1285-8. PubMed ID: 8723486
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of HIV infection of resting peripheral blood lymphocytes by nucleosides.
Watson AJ; Wilburn LM
AIDS Res Hum Retroviruses; 1992 Jul; 8(7):1221-7. PubMed ID: 1325818
[TBL] [Abstract][Full Text] [Related]
12. [Anti-HIV therapy (1987-1994): from nothing to confusion].
Lissen E
Med Clin (Barc); 1995 Apr; 104(12):463-7. PubMed ID: 7739285
[No Abstract] [Full Text] [Related]
13. Zalcitabine and didanosine.
Lipsky JJ
Lancet; 1993 Jan; 341(8836):30-2. PubMed ID: 8093278
[No Abstract] [Full Text] [Related]
14. Altered drug sensitivity, fitness, and evolution of human immunodeficiency virus type 1 with pol gene mutations conferring multi-dideoxynucleoside resistance.
Maeda Y; Venzon DJ; Mitsuya H
J Infect Dis; 1998 May; 177(5):1207-13. PubMed ID: 9593005
[TBL] [Abstract][Full Text] [Related]
15. Synergistic anti-human immunodeficiency virus type 1 effect of hydroxamate compounds with 2',3'-dideoxyinosine in infected resting human lymphocytes.
Malley SD; Grange JM; Hamedi-Sangsari F; Vila JR
Proc Natl Acad Sci U S A; 1994 Nov; 91(23):11017-21. PubMed ID: 7972000
[TBL] [Abstract][Full Text] [Related]
16. Resistance of human immunodeficiency virus type 1 to antiretroviral agents: a review.
Erice A; Balfour HH
Clin Infect Dis; 1994 Feb; 18(2):149-56. PubMed ID: 7512829
[No Abstract] [Full Text] [Related]
17. Inhibition of human immunodeficiency virus type 1 replication in vitro by the bisheteroarylpiperazine atevirdine (U-87201E) in combination with zidovudine or didanosine.
Campbell TB; Young RK; Eron JJ; D'Aquila RT; Tarpley WG; Kuritzkes DR
J Infect Dis; 1993 Aug; 168(2):318-26. PubMed ID: 7687641
[TBL] [Abstract][Full Text] [Related]
18. Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives.
Pauwels R; Andries K; Desmyter J; Schols D; Kukla MJ; Breslin HJ; Raeymaeckers A; Van Gelder J; Woestenborghs R; Heykants J
Nature; 1990 Feb; 343(6257):470-4. PubMed ID: 1689015
[TBL] [Abstract][Full Text] [Related]
19. [Reverse transcriptase inhibitors as anti-HIV agents].
Shirasaka T; Mitsuya H
Nihon Rinsho; 1993 Sep; 51 Suppl():192-9. PubMed ID: 7505846
[No Abstract] [Full Text] [Related]
20. (-)-2'-deoxy-3'-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro.
Coates JA; Cammack N; Jenkinson HJ; Jowett AJ; Jowett MI; Pearson BA; Penn CR; Rouse PL; Viner KC; Cameron JM
Antimicrob Agents Chemother; 1992 Apr; 36(4):733-9. PubMed ID: 1380229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
